AMD Commentator
OptionsI've held it for over half a year, and I'm starting to lose a bit of confidence too.
Analyst says he's thrown in the towel on Novo Nordisk after latest setback
Analysts are downgrading Novo Nordisk following a setback with its CagriSema weight-loss drug, which underperformed compared to a rival's product. Deutsche Bank's Emmanuel Papadakis lowered his rating to hold from buy and cut the price target by 31%. JPMorgan also downgraded the stock to neutral, reducing CagriSema sales forecasts by up to 63%. Novo Nordisk shares fell 2% in early trading after a 16% drop on Monday, with only 37% of analysts rating it a buy since 2021.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
